Pathophysiology of coronary microvascular dysfunction

Vascul Pharmacol. 2023 Oct 26:107239. doi: 10.1016/j.vph.2023.107239. Online ahead of print.ABSTRACTThe term "coronary microvascular dysfunction" (CMD) encompasses several pathogenetic mechanisms resulting in functional and/or structural changes in the coronary microcirculation. CMD often determines angina and myocardial ischemia in a broad spectrum of cardiovascular diseases, including patients with ischemia with non-obstructive coronary arteries or ischemia with obstructive coronary artery disease, infarction with non-obstructive coronary arteries, cardiomyopathies, the Takotsubo syndrome and heart failure, especially heart failure with preserved ejection fraction. In this article, we provide updated evidence regarding the pathophysiological mechanisms underlying CMD across the different cardiovascular diseases, aiming to pave the way for further research and the development of novel strategies for a precision medicine approach.PMID:37898380 | DOI:10.1016/j.vph.2023.107239
Source: Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research